Material Insights · Understanding the Material World

Combination antiretroviral therapy: Materials

Materials it needs

The commodities and chemicals it needs per unit, its share of each one's demand and how critical each is

Made of
  • API Small-molecule APIs criticality medium The active drug ingredients are made largely by generic producers in a few countries with pharmaceutical capacity, such as India, Brazil and Thailand [4].
Uses

as of 2026-11-11. No source gives amounts; criticality is the writer's judgement from the concentration of generic production.

Critical materials

The materials whose supply could hold it back

  • Active ingredients: low prices rest on generic production in a few countries with pharmaceutical capacity, such as India, Brazil and Thailand [4].
  • Patents: as resistance grows or better drugs arrive, patients must move to newer drugs that are still under patent and cost more [4].
  • Funding: in 2025, US$ 17.6 billion was available for the AIDS response in low- and middle-income countries, about 20% below the US$ 21.9 billion needed each year by 2030 [2].

as of 2026-11-11

Sources

  1. Antiretroviral Drug Discovery and Development National Institute of Allergy and Infectious Diseases (NIH)
  2. Fact sheet 2026 UNAIDS, 2026
  3. The impact of patents on access to medicines MSF Access Campaign (Médecins Sans Frontières), 2017